Skip to content

Rapport Therapeutics, Inc. RAPP Balance Sheet Statement

FY'25FY'24FY'23
$52.65M-7.3%$56.81M-19.0%$70.17M
$437.89M+76.2%$248.48M+221%$77.31M
$498.56M+60.9%$309.8M+105%$150.87M
$2.98M-15.7%$3.53M+84.2%$1.92M
$512.43M+62.7%$314.93M+103%$155.42M
$12.74M+217%$4.02M
$19.05M+117%$8.77M-0.4%$8.8M
$27.78M+192%$9.51M-34.3%$14.48M
$48K+29.7%$37K+825%$4K
-$235.23M-90.1%-$123.75M-172%-$45.44M
$484.65M+58.7%$305.43M+1,291%-$25.63M-155%
$512.43M+62.7%$314.93M+103%$155.42M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Rapport Therapeutics, Inc.'s total assets?
Rapport Therapeutics, Inc. (RAPP) holds $497.6M in total assets, up 64.7% year over year.
How much debt does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. carries $10.8M in total debt against $471.5M of shareholders' equity, a debt-to-equity ratio of 0.02.
How much cash does Rapport Therapeutics, Inc. have?
Rapport Therapeutics, Inc. holds $78.1M in cash and equivalents.
Can Rapport Therapeutics, Inc. cover its short-term obligations?
Its current ratio is 27.08 — current assets exceed current liabilities.
Where does Rapport Therapeutics, Inc.'s balance sheet data come from?
Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.